Business context and reporting period
Filing identity: The request identifies Skyai, Inc., but the supplied Form 10-K is for Sharps Technology, Inc. (Nasdaq: STSS; warrants: STSSW). Confirm the intended issuer before relying on this summary. The filing covers the fiscal year ended December 31, 2022, with 2021 comparative results.
Sharps is a pre-revenue medical-device company developing and commercializing safety syringes. Its Securegard and Provensa products combine needle-safety and reuse-prevention features with claimed ultra-low dead space. In July 2022, it acquired Safegard’s Hungarian manufacturing facility and related assets. It also entered into a four-year collaboration with Nephron covering manufacturing support, prefillable syringe systems and pharma services; Nephron was appointed exclusive U.S. distributor for covered products.
Financial performance and liquidity
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $2.28 million | $1.69 million |
| General and administrative expense | $6.46 million | $2.81 million |
| Operating loss | $8.74 million | $4.50 million |
| Net loss | $4.64 million | $4.66 million |
| Basic and diluted loss per share | $0.57 | $0.96 |
| Operating cash used | $6.43 million | $3.15 million |
| Investing cash used | $3.12 million | $2.34 million |
There were no sales, so revenue margins are not meaningful. Net loss was nearly flat year over year despite higher operating expenses, chiefly because of a $5.39 million fair-value gain on contingent stock and warrant liabilities. The company reported $1.32 million of net interest expense, including substantial accretion on its 2021 bridge financing.
Cash and cash equivalents at year-end are reported as $4.17 million in the balance sheet and cash-flow statement; the MD&A separately states $4.11 million. Working capital was $2.42 million, versus a $1.16 million deficit in 2021. Total liabilities were $2.20 million, including $1.15 million of warrant liabilities; the $2.0 million bridge note was repaid from IPO proceeds. The filing reports $7.00 million in net fixed assets and $9.64 million in stockholders’ equity.
Operating cash use increased as staffing, public-company costs and development activity grew. Investing outflows included $2.37 million for the Safegard acquisition. The April 2022 IPO generated approximately $14.2 million net; about $10 million had been used by year-end. A February 2023 offering subsequently raised approximately $3.2 million net.
Material changes versus 2021
- G&A increased 130% to $6.46 million, driven by higher payroll and consulting, marketing, insurance, professional fees and public-company expenses.
- R&D rose 35% to $2.28 million, reflecting facility staffing and costs after the Safegard acquisition, partially offset by lower pre-acquisition facility operating payments.
- Sharps acquired and began operating its 41,000-square-foot Hungary facility in July 2022; fixed assets increased to $7.00 million net.
- The company completed its IPO, repaid the $2.0 million bridge note and moved from a working-capital deficit to positive working capital.
- Net loss improved slightly, but this did not reflect commercial revenue: the company remained pre-revenue, and the year’s results included a sizable noncash derivative fair-value gain.
Outlook, risks and unusual items
- Management intends to build inventory, increase production capacity and commercialize Securegard first. Provensa commercialization has been delayed by final-assembly optimization. The filing says no orders had been received to date.
- Nephron collaboration and distribution arrangements are potential routes to market, not evidence of realized sales. The filing gives differing expected prefillable-product supply dates—mid-2023 in one discussion and the fourth quarter of 2023 elsewhere—and also contains a reference to orders in the second quarter of 2022. Treat these timelines as uncertain.
- Key risks include continued losses and cash burn, need for additional capital, manufacturing scale-up and product delays, lack of customer orders, competition, regulatory requirements, and product-liability exposure. Product-liability coverage was reported at $5 million.
- Outstanding warrants are liability-classified and remeasured at fair value, which can materially affect reported earnings. At December 31, 2022, 9.05 million warrants were outstanding; 10.41 million options and warrants were excluded from diluted EPS as antidilutive.
- A 2% royalty on net sales related to certain intellectual property remains in place. The company also disclosed a dispute with co-chairman Alan Blackman regarding termination of his employment agreement and his allegations of “good reason” and retaliation; the company said it considered the allegations without merit. No material litigation was reported as pending in the legal-proceedings section.
- One Series A preferred share held by Mr. Blackman carries 29.5% of director-election voting power and specified sale-related rights. Further equity issuance may dilute shareholders. The company reported effective disclosure controls, but its internal-control report was omitted under the transition applicable to newly public companies; the auditor did not opine on internal-control effectiveness.
- The independent auditor issued an unqualified opinion on the financial statements. No cash dividends are planned. The filing reports no material off-balance-sheet arrangements.
Important facts for investors to verify
- Confirm that Sharps Technology, Inc.—not Skyai, Inc.—is the intended issuer and verify the filing period.
- Reconcile the year-end cash discrepancy ($4.17 million in the financial statements versus $4.11 million in MD&A) and review subsequent cash use and financing needs.
- Check whether Nephron-related supply milestones were achieved, whether commercial orders were obtained, and whether the disclosed timing estimates changed.
- Assess production readiness, inventory quality and the remaining Provensa assembly work, alongside regulatory clearances in intended markets.
- Review warrant terms and dilution potential, including the February 2023 offering, and evaluate the effect of liability remeasurement on earnings.
- Monitor the Blackman employment dispute, related-party obligations, and the ongoing 2% royalty on applicable net sales.